Overview

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is a Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study ,Target population is Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma (UPS) and Alveolar Soft Tissue Sarcoma (ASPS) . The purpose of this study was to evaluate the safety and efficacy of combination of Camrelizumab and Apatinib in the treatment of unresectable UPS and ASPS
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Treatments:
Apatinib